In Resectable Non–Small Cell Lung Cancer, Perioperative Use of Tislelizumab Alone or With Chemotherapy Improved Outcomes – The ASCO Post
In patients with resectable non–small cell lung cancer (NSCLC), perioperative treatment involving the checkpoint inhibitor tislelizumab led to a statistically significant benefit in event-free survival and a favorable trend for overall survival, investigators for the phase III RATIONALE-315 trial have reported. 1 “Major pathologic and complete pathologic responses were also significantly improved with neoadjuvant tislelizumab plus platinum-doublet chemotherapy,” said Dongsheng Yue, MD, of Tianjin Medical